The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
VJVirtual | Dara-KRd for myeloma
Ola Landgren, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the use of daratumumab with carfilzomib, lenalidomide, and dexamethasone (dara-KRd) for the treatment of newly diagnosed multiple myeloma. Prof. Landgren goes on to highlight how the achievement of durable responses without the use of transplantation is important in light of the current COVID-19 pandemic that may impact immunosuppressed patients. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
